When a new virus emerges, the fastest way to prove a vaccine works is a Phase 3 clinical trial: vaccinate thousands of people, give placebos to thousands of others, and wait to see who gets sick. But once effective vaccines exist, running these trials becomes ethically and practically impossible. We cannot give placebos when proven life-saving alternatives are available.
To evaluate updated boosters, pediatric doses, or entirely new vaccine technologies, scientists rely on correlates of protection—measurable biological markers (like antibody levels in the blood) that reliably predict clinical immunity.
However, the field faces a fundamental measurement problem. If Lab A measures an antibody titer of 100 using a proprietary test, and Lab B measures a titer of 500 using a live-virus assay, is the second vaccine five times more effective, or are the labs simply using different rulers? As Youyi Fong et al. note in their analysis of the Janssen ENSEMBLE trial, benchmarking the relative efficacy of disparate vaccine technologies—such as viral vectors, mRNA, and protein subunits—is severely hindered by the lack of a standardized biological scale (Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial).
The solution is a set of statistical and biological calibration techniques known as assay harmonization. By anchoring idiosyncratic laboratory readouts to universal reference standards, researchers have discovered something remarkable: the underlying mathematical relationship between antibody levels and clinical protection is highly stable and platform-agnostic.
The Tower of Babel in Serological Assays
Why do different laboratory tests yield completely different numbers for the same blood sample? The variance stems from several layers of experimental design:
- Proprietary Scales and Targets: Commercial antibody tests target different regions of a viral protein (e.g., different domains of the SARS-CoV-2 Spike protein) and report results in arbitrary, manufacturer-specific units. As shown by Raquel Rubio‐Acero et al., even two highly reliable commercial assays can diverge significantly because they use different viral targets and proprietary measurement scales (In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients).
- Biological Baseline Noise: In animal testing or cross-immunity studies, the baseline potency of the animal antisera itself can vary wildly between batches, skewing measurements independently of the virus's actual genetic characteristics (M. N. Asatryan et al., Mathematical model for assessing the level of cross-immunity between strains of influenza virus subtype H<sub>3</sub>N<sub>2</sub>).
- Systematic Assay Discrepancies: Laboratory assays that measure neutralizing antibodies often exhibit systematic, predictable differences in titer levels rather than random noise (Yunda Huang et al., Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation).
Without a way to translate between these scales, a threshold of protection established in one clinical trial is useless to researchers evaluating a different vaccine in another part of the world.
The Mechanism: Reference Calibration
To build a universal scale, researchers use reference calibration. Instead of relying on raw assay outputs, they apply a mathematical conversion coefficient derived from a shared, universally available biological material.
[Raw Assay Output (Lab A)] ───× (Conversion Factor A) ──┐
▼
[Universal Unit (e.g., BAU/mL)]
▲
[Raw Assay Output (Lab B)] ───× (Conversion Factor B) ──┘
As explained by Inge Kroidl et al., this mechanism allows raw outputs from proprietary assays to be expressed in a common metric, such as the World Health Organization's Binding Antibody Units (BAU) (Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison).
This approach has deep historical precedent. For example, David Goldblatt et al. established a human standard reference serum called "007sp" to replace dwindling older standards, ensuring that new pneumococcal vaccines could be directly compared to older, already licensed vaccines (Establishment of a New Human Pneumococcal Standard Reference Serum, 007sp).
When an international physical standard is unavailable, researchers can achieve a similar effect by using a local biological anchor. Kristen Earle et al. demonstrated that expressing vaccine-induced antibody levels as a ratio relative to the levels found in human convalescent sera within the same study serves as an effective common reference point, successfully aligning data from highly diverse sources (Evidence for antibody as a protective correlate for COVID-19 vaccines).
(Interestingly, this mathematical principle of using multi-marker calibration formulas to correct for systematic assay interference spans other medical domains as well, such as adjusting for immunoglobulin subtypes to correct false diagnostic signals in blood disorders (Xiaozhe Li et al., The identification and correction of pseudohypercalcemia).)
Intuition: The Platform-Agnostic Protection Curve
Why does this calibration work so beautifully? The intuition lies in a profound biological reality: once you strip away the measurement noise of individual laboratory assays, the human immune system's relationship with clinical protection is remarkably uniform.
When raw antibody titers from different clinical trials are plotted against vaccine efficacy, the data looks like a scattered mess. But when David S. Khoury et al. normalized these titers to the mean level of a reference group, the seemingly conflicting datasets collapsed onto a single, consistent mathematical protection curve (Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection).
This means that whether an antibody was triggered by an mRNA strand, a viral vector, or a purified protein subunit, a standardized concentration of that antibody provides the exact same level of clinical protection.
Vaccine Efficacy (%)
100 │ /• (mRNA)
│ /
50 │ •──────┘ (Protein Subunit)
│ /
0 ┼────┴──────────────────────────
Low High
Standardized Antibody Level
This platform-agnostic consistency has been validated across several major Phase 3 trials:
- Viral Vectors: David Benkeser et al. demonstrated that standardizing anti-spike IgG and neutralizing titers into international units reveals a predictable, platform-agnostic correlation with protection for the AstraZeneca AZD1222 vaccine (Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine).
- Protein Subunits: Youyi Fong et al. confirmed that the statistical relationship between antibody levels and protection in the Novavax PREVENT-19 trial perfectly mirrors that of mRNA platforms once harmonized into WHO International Units (Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial).
Applications and the Frontiers of Immunobridging
By establishing these universal metrics, regulatory bodies and scientists can perform immunobridging. Instead of waiting for thousands of trial participants to naturally encounter a virus in the wild, researchers can run small, rapid laboratory studies. If a new booster or a pediatric dose elicits antibody levels that meet or exceed the standardized international threshold, efficacy can be reliably inferred (Yunda Huang et al., Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation; Ji Youn Lim et al., Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2).
The Challenge of Viral Evolution
While antibody calibration is highly effective for a stable virus, rapid viral evolution introduces a new complication. As Bo Zhang et al. point out in their study of the Omicron variant, the field currently lacks "variant-invariant" markers. When a virus mutates significantly, the absolute antibody thresholds required for protection shift, meaning calibration frameworks must be continuously updated as the viral landscape evolves (Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial).
The Cellular "Backup" System
Finally, while standardized antibody titers are excellent predictors, they do not capture the entire immune response. Dean Follmann et al. discovered that while standardized units allow for flawless cross-trial comparisons, vaccines actually maintain better clinical efficacy at lower antibody titers than monoclonal antibody treatments (Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration). This discrepancy highlights the critical, unmeasured backup role played by cellular immunity (like memory B cells and T cells).
In fact, mapping these cellular gatekeepers is the next major frontier. For instance, Édouard Lhomme et al. showed that measuring "helper" CD4+ T cell activity as early as two weeks post-vaccination can predict long-term "killer" CD8+ T cell responses (Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy). Just like antibodies, validating these early cellular markers across diverse delivery systems will be essential to establishing the next generation of universal vaccine benchmarks.
Key Foundational Work
Establishment of a New Human Pneumococcal Standard Reference Serum, 007sp (2011) — contributed 1 concept elements to this direction.
Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy (2016) — contributed 1 concept elements to this direction.